The Independent Uganda: You get the Truth we Pay the Price
bNAb therapy might offer a future alternative to daily ART for people living with HIV
Los Angeles, U.S. | Xinhua | Individuals with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs), according to a new study published Wednesday in the journal Nature.
The findings suggest that combination bNAb therapy might offer a future alternative to daily ART for people living with HIV, said the study.
The research was led by scientists at the U.S. National Institute of Allergy and Infectious Diseases. They tested a dual combination of bNAbs, called 3BNC117 and 10-1074, targeting different parts of the surface of HIV.
The researchers conducted a two-component clinical trial between September 2018 and January 2021. They found that combination bNAb therapy can be highly effective in suppressing HIV in the absence of ART for extended periods, provided that antibody-resistant virus is not present at the time individuals begin antibody treatment.
*****
Xinhua
